IL1B and deep vein thrombosis: CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) demonstrated for the first time that inhibiting the interleukin (IL)-1b pathway can lower the risk of cardiovascular events in patients with coronary artery disease (CAD) by about 17% (27).